PFE

Pfizer
D

PFE

Arincen59/100B

Pfizer balance sheet 1985–2026

Pfizer had 14.27B USD in cash and short-term investments on 27 September 2026, against total debt of 62.67B USD: net debt of 48.40B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
1.82B1.14B1.04B2.85B416.00M1.94B1.79B1.12B1.14B1.34B2.60B
Short-term investments
12.45B12.45B19.43B9.84B22.32B29.13B10.44B8.53B17.69B18.65B15.26B
14.27B13.60B20.48B12.69B22.73B31.07B12.22B9.65B18.83B19.99B17.85B
Cash growth
-4.75%-33.60%+61.36%-44.18%-26.83%+154.18%+26.72%-48.78%-5.80%+12.00%-23.36%
Receivables
14.19B15.84B14.78B15.54B14.53B15.75B11.18B9.51B11.40B11.27B11.27B
Inventory
10.02B10.65B10.85B10.19B8.98B9.06B8.05B7.07B7.51B7.58B6.78B
Other current assets
6.52B2.81B4.25B4.91B5.02B3.82B3.65B6.58B12.19B2.30B3.05B
Total current assets
45.01B42.90B50.36B43.33B51.26B59.69B35.07B32.80B49.93B41.14B38.95B
Property, plant and equipment
19.05B21.53B18.39B18.94B16.27B14.88B13.75B12.97B13.39B13.87B13.32B
Long-term investments
1.45B1.74B2.23B15.37B15.07B21.53B20.26B20.15B2.77B7.02B7.12B
Goodwill and intangibles
117.42B125.00B123.94B132.68B94.75B74.35B77.89B82.14B88.62B104.69B107.10B
Goodwill
71.46B71.26B68.53B67.78B51.38B49.21B49.56B48.20B53.41B55.95B54.45B
Intangible assets
45.96B53.73B55.41B64.90B43.37B25.15B28.34B33.94B35.21B48.74B52.65B
Other non-current assets
10.02B7.30B9.82B12.47B13.16B7.68B4.57B17.63B2.80B3.23B3.32B
Total assets
204.54B208.16B213.40B226.50B197.21B181.48B154.23B167.49B159.42B171.80B171.62B
Accounts payable
4.07B5.24B5.63B6.71B6.81B5.58B4.28B3.89B4.67B4.66B4.54B
Deferred revenue
0.00784.00M1.51B2.70B2.52B3.07B1.11B0.000.000.000.00
Short-term debt
2.67B3.48B6.95B10.35B2.93B2.24B2.70B16.19B8.84B9.94B10.66B
Other current liabilities
21.58B18.32B23.20B23.32B25.99B28.27B14.61B14.14B15.04B13.33B13.54B
Total current liabilities
31.73B36.98B43.00B47.79B42.14B42.67B25.92B37.30B31.86B30.43B31.12B
Long-term debt
60.00B61.64B57.41B60.50B31.93B34.76B35.57B34.65B32.91B32.67B30.40B
Other non-current liabilities
21.58B18.07B20.09B28.28B26.20B26.24B25.20B26.54B27.20B33.15B19.51B
Lease obligations, current
0.000.00356.00M0.000.000.000.000.000.000.000.00
Lease obligations, long-term
0.002.29B2.29B0.000.000.000.001.03B-21.35B-27.00B-12.17B
Total liabilities
115.24B121.39B124.90B137.21B101.29B104.01B90.76B104.15B95.66B100.14B111.78B
Common stock and paid-in capital
482.00M481.00M480.00M478.00M476.00M473.00M470.00M468.00M467.00M464.00M461.00M
Retained earnings
115.33B114.61B116.73B118.35B125.66B103.39B96.77B97.67B89.55B85.29B71.77B
Accumulated other comprehensive income
-6.97B-8.07B-7.84B-7.96B-8.30B-5.90B-11.69B-11.64B-11.28B-9.32B-11.04B
Shareholders' equity
89.00B86.48B88.20B89.01B95.66B77.20B63.24B63.14B63.41B71.31B59.54B
Minority interest
299.00M299.00M294.00M274.00M256.00M262.00M235.00M303.00M351.00M348.00M296.00M
62.67B67.42B66.99B70.85B34.86B37.00B38.27B50.84B41.75B42.61B41.06B
Net cash
-48.40B-53.82B-46.52B-58.16B-12.13B-5.93B-26.05B-41.19B-22.91B-22.61B-23.21B
Working capital
13.28B5.91B7.36B-4.46B9.12B17.02B9.15B-4.50B18.07B10.71B7.83B
Book value per share
15.4815.2115.4715.5916.6913.5311.2311.1310.6111.779.67
Tangible book value
-28.42B-38.52B-35.74B-43.67B916.00M2.85B-14.65B-19.00B-25.22B-33.38B-47.55B
Tangible book value per share
-4.94-6.77-6.27-7.650.160.50-2.60-3.35-4.22-5.51-7.72
Current ratio
1.421.161.170.911.221.401.350.881.571.351.25
Debt to equity
0.700.780.760.800.360.480.610.810.660.600.69

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Pfizer's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.